Active substance
Estriol
- UK MHRA 8
- NHS prices 5
- Safety 4
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| BLISSEL 50 MICROGRAMS/G VAGINAL GEL | PL 20663/0003 | ITALFARMACO SA | POM |
| ESTRIOL 0.01% W/W CREAM | PL 23138/0012 | MARLBOROUGH PHARMACEUTICALS LIMITED | POM |
| ESTRIOL 0.5 MG/G VAGINAL CREAM | PL 13159/0018 | DR AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL | POM |
| ESTRIOL 0.5MG PESSARY | PL 39699/0113 | ASPEN PHARMA TRADING LIMITED | POM |
| ESTRIOL 1MG/G CREAM | PL 39699/0058 | ASPEN PHARMA TRADING LIMITED | POM |
| GYNEST CREAM 0.01% W/W | PL 23138/0012 | MARLBOROUGH PHARMACEUTICALS LIMITED | POM |
| IMVAGGIS 0.03 MG PESSARY | PL 42714/0001 | BESINS HEALTHCARE (UK) LIMITED | POM |
| OVESSE 1 MG/G VAGINAL CREAM | PL 39699/0118 | ASPEN PHARMA TRADING LIMITED | P |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Estriol 0.01% vaginal cream with applicator | £40.40 | 1 pack | 1 Oct 2026 |
| NHS Drug Tariff | Estriol 1mg/g vaginal cream with applicator | £5.78 | 15 gram | 1 Oct 2026 |
| NHS Drug Tariff | Estriol 30microgram pessaries | £13.38 | 24 pessary | 1 Oct 2026 |
| NHS Drug Tariff | Estriol 500microgram pessaries | £5.78 | 15 pessary | 1 Oct 2026 |
| NHS Drug Tariff | Estriol 50micrograms/g vaginal gel with applicator | £18.90 | 30 gram | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- EMA PRAC 14 May 2020 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: Yes - EMA PRAC 12 Mar 2020 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: No - EMA PRAC 16 Jan 2020 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: No - EMA PRAC 3 Oct 2019 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.